Curing Blindness Through Gene Therapy Might Soon Be Allowed By The FDA

Patients whose blindness is a result of an RPE65 gene might soon consider Luxturna, a form of gene therapy that improves vision. Its approval will soon be deliberated by the U.S. Food and Drug Administration.